Äèñêóññèîííûé Êëóá

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Òåðàïèÿ > Ôîðóì äëÿ îáùåíèÿ âðà÷åé-òåðàïåâòîâ

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #1  
Ñòàðûé 21.12.2015, 21:41
Àâàòàð äëÿ Alexey2301
Alexey2301 Alexey2301 âíå ôîðóìà ÂÐÀ×
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 10.01.2010
Ãîðîä: Ñàìàðà
Ñîîáùåíèé: 355
Ñêàçàë(à) ñïàñèáî: 19
Ïîáëàãîäàðèëè 68 ðàç(à) çà 65 ñîîáùåíèé
Alexey2301 ýòîò ó÷àñòíèê èìååò îòëè÷íóþ ðåïóòàöèþ íà ôîðóìå
Äâóõñòîðîííÿÿ ïíåâìîíèÿ íà ôîíå ëåéêîïåíèè

Óâàæàåìûå êîëëåãè, ïðîøó Âàøåé ïîìîùè!
Ïàöèåíòêà ïîñòóïèëà ñ æàëîáàìè íà îäûøêó â ïîêîå, êàøåëü ñ ìîêðîòîé ñëèçèñòî-ãíîéíîãî õàðàêòåðà, ïîâûøåíèå òåìïåðàòóðû òåëà äî ôåáðèëüíûõ öèôð, ñëàáîñòü, áûñòðóþ óòîìëÿåìîñòü, ïåòåõèàëüíóþ ñûïü íà òóëîâèùå è â/ê ñ 2õ ñòîðîí.
Èç àíàìíåçà: Ïî äàííûì àìáóëàòîðíîé êàðòû ñ 2010 ãîäà â ÎÀÊ îòìå÷àåòñÿ ñíèæåíèå óðîâíÿ Ëå äî 3 òûñ., îáñëåäîâàëàñü ó ãåìàòîëîãà, ïðîâîäèëèñü ñòåðíàëüíûå ïóíêöèè. Äàííûõ çà çàáîëåâàíèå êðîâè íå ïîëó÷åíî, ïîëó÷àëà ìåòèëóðàöèë, ôîëèåâóþ êèñëîòó. Íàáëþäàëàñü ñ äèàãíîçîì ëåéêîïåíèÿ íåÿñíîãî ãåíåçà.  ÎÀÊ ñîõðàíÿëàñü ëåéêîïåíèÿ, òðîìáîöèòîïåíèÿ, ëèìôîöèòîç äî 64%; ñïëåíîìåãàëèÿ.Ïðîâîäèëîñü èììóíîôåíîòïèðîâàíèå (ïðèçíàêîâ çàáîëåâàíèÿ êðîâè íå ïîëó÷åíî).  ìàðòå 2015 ãîäà ñòàëà îòìå÷àòü ïîÿâëåíèå âûñûïàíèé íà ãîëåíÿõ ñ äâóõ ñòîðîí, ïî äàííûì ÊÒ ÎÃÊ ïðèçíàêè äèññåìèíèðîâàííîãî ïðîöåññà (î÷àãè íàêàïëèâàþò êîíòðàñò); óçëîâàòàÿ ýðèòåìà?. Îñìîòðåíà ðåâìàòîëîãîì àíàëèç êðîâè íà ÀÒ ê ÄÍÊ 15,6 (äî 25 ÅÄ), ÀÍÔ 4,39 (äî 1); Scl 70 145 (äî 25); Ïîñòàâëåí äèàãíîç óçëîâàòàÿ ýðèòåìà. Íàçíà÷åí ïðåäíèçîëîí 2 òàáë., ïëàêâåíèë. Çàïîäîçðåí ñàðêîèäîç ë¸ãêèõ. Ó÷èòûâàÿ íàëè÷èå ïðèçíàêîâ äèññåìèíèðîâàííîãî ïðîöåññà íàïðàâëåíà íà äîîáñëåäîâàíèå â îíêîäèñïàíñåð ðåçóëüòàòû ÊÒ ïåðåñìîòðåíû (ïðèçíàêè äèññåìèíèðîâàííîãî ïðîöåññà susp mts).  óñëîâèÿõ ÎÊÎÄ ïîâòîðíî ïðîâåäåíà ÊÒ ÎÃÊ (èþëü 2015ã.) - ïðèçíàêè õðîíè÷åñêîãî áðîíõèòà, ëèìôàäåíîïàòèÿ êîðíÿ ïðàâîãî ë¸ãêîãî (ðåàêòèâíûé õàðàêòåð ïðîöåññà)Ïîëîæèòåëüíàÿ äèíàìèêà íà ôîíå ïðåäíèçîëîíà???). Ïðîâåäåíà áèîïñèÿ íàäêëþ÷è÷íûõ ëèìôîóçëîâ (ãèïåðïëàçèÿ ëèìôîèäíûõ ýëåìåíòîâ ñ âûðàæåííîé ìàêðîôàãàëüíîé ðåàêöèåé). Ïî äàííûì ÔÁÑ, ÔÃÄÑ äàííûõ çà ñïåöèôè÷åñêèé ïðîöåññ íå ïîëó÷åíî. Òîòàëüíàÿ ïîëèïýêòîìèÿ ñèãìîâèäíîé êèøêè äàííûõ çà ñïåöèôè÷åñêèé ïðîöåññ íå ïîëó÷åíî (íî ðåçóëüòàòû áèîïñèè íå ïðåäñòàâëåíû). Ïîâòîðíî íàïðàâëåíà ê ïóëüìîíîëîãó, ðåâìàòîëîãó. Ðåêîìåíäîâàíî ïðîäîëæèòü ïðèåì ÑÃÊÑ, ïëàêâåíèëà (îêòÿáðü 2015ã). 06.12.15ã. Ñòàëà îòìå÷àòü óõóäøåíèå ñàìî÷óâñòâèÿ, ïîâûøåíèå òåìïåðàòóðû òåëà äî ôåáðèëüíûõ öèôð, îäûøêó ïðè íàãðóçêå. Ãîñïèòàëèçèðîâàíà â èíôåêöèîííîå îòäåëåíèå ñ ïîäîçðåíèåì íà ãðèïï. Ïðîâîäèëàñü à/á è ïðîòèâîâèðóñíàÿ òåðàïèÿ. 11.12.15ã. Ïåðåâåäåíà â îòäåëåíèå òåðàïèè â ñâÿçè ñ ïðèçíàêàìè ïíåâìîíèè ïî ðåíòãåíîãðàììå îðãàíîâ ãðóäíîé êëåòêè, â ÎÀÊ ñíèæåíèå ïîêàçàòåëåé êðîâè (ãåìîãëîáèí 89ã/ë, Ëå 0,9 òûñ, Òð 79 òûñ.). Ïî ÊÒ ÎÃÊ — äâóõñòîðîííÿÿ ïîëèñåãìåíòàðíàÿ ïíåâìîíèÿ (ñ 12.12.15ã. Íàçíà÷åí ïðåäíèçîëîí 40 ìã/ñóò – ïîäîçðåíèå íà ïîðàæåíèå ë¸ãêèõ íà ôîíå ñàðêîèäîçà), ïàöèåíòêà ïåðåâåäåíà â îòäåëåíèå ïóëüìîíîëîãèè, ïðè ïîñòóïëåíèè – ñîñòîÿíèå òÿæåëîå, äûõàíèå ñàìîñòîÿòåëüíîå, Sp 80% íà ôîíå êèñëîðîäà 90%.  îòäåëåíèè ïðîäîëæåíà à/á òåðàïèÿ (ëåâîôëîêñàöèí 1ãð /ñóò, àìîêñèêëàâ 1,2 ãð. 3ð ñóò.)  ÎÀÊ Ëå 0,9òûñ, òð. 76òûñ, ãåìîãëîáèí 106ã/ë, Ýð 3,1 *10/9/ë. Ñ ðåàêòèâíûé áåëîê 330 ìã/ë, àëüáóìèí 18 ã/ë, îáùèé áåëîê 54 ã/ë, îñòàëüíûå á/õ àíàëèçû êðîâè â íîðìå, ÂÈ× îòð., ãåïàòèòû, RW îòð.  ñâÿçè ñ òÿæåñòüþ ñîñòîÿíèÿ ñîáðàí êîíñèëèóì â ñîñòàâå ðåâìàòîëîãà, ãåìàòîëîãà âûñêàçàíî ïðåäïîëîæåíèå î ïîðàæåíèè ë¸ãî÷íîé òêàíè íà ôîíå ÑÇÑÒ íàçíà÷åí ïðåäíèçîëîí 300 ìã/ñóò), íà ôîíå ïðîâîäèìîé ïóëüñòåðàïèè ïðåäíèçîëîíîì ëèõîðàäêà äî 39Ñ, ñíèæåíèå ïîêàçàòåëåé Sp, ñÃÊÑ îòìåíåíû. Ïðîâåäåíà ñòåðíàëüíàÿ ïóíêöèÿ (â ðàáîòå). Ïî äàííûì ÓÇÈ ëèìôàäåíîïàòèÿ ïåðèôåðè÷åñêèõ ë/ó, ñåëåçåíêà 62 ñì2.
Ñ 18.12.15ã. ê ëå÷åíèþ äîáàâëåí áèñåïòîë.
ß òàê äóìàþ, ÷òî ïîêà òîëüêî æäàòü.
Îòâåòèòü ñ öèòèðîâàíèåì
  #2  
Ñòàðûé 12.01.2016, 23:47
Àâàòàð äëÿ Tarja
Tarja Tarja âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 08.08.2007
Ãîðîä: Belarus
Ñîîáùåíèé: 1,262
Ïîáëàãîäàðèëè 256 ðàç(à) çà 252 ñîîáùåíèé
Tarja ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTarja ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTarja ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTarja ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTarja ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTarja ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTarja ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTarja ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTarja ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTarja ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåTarja ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Çäðàâñòâóéòå. Íå âèäåëà Âàøó òåìó, ê ñîæàëåíèþ. Êàêèå íîâîñòè, Àëåêñåé? Ñòåðíàëüíàÿ ïóíêöèÿ ïðîÿñíèëà ñèòóàöèþ?
Ïàðà ìûñëåé
Ïðè ëåéêîïåíèè è òðîìáîöèòîïåíèè íå íàçíà÷àëà áû ôòîðõèíîëîíû.
Íå çàáûâàéòå î âîçìîæíîñòè èíâàçèâíîãî ìèêîçà ïðè òàêîé ëåéêîïåíèè (èìåþ ïå÷àëüíûé îïûò èíâàçèâíîãî àñïåðãèëëåçà ó ïàöèåíòà ñ ëåêîöèòàìè 2-3õ10/9, íà ÊÒ-"ìàòîâîå ñòåêëî").
Õîòåëîñü áû íà ÊÒ, êîíå÷íî, ãëÿíóòü.
Ñàðêîèäîç ìîæåò è åñòü, íî íå îí îáóñëîâëèâàåò òÿæåñòü, ÈÌÕÎ.
__________________
Çäîðîâüÿ Âàì è Âàøèì áëèçêèì.
Îòâåòèòü ñ öèòèðîâàíèåì
  #3  
Ñòàðûé 14.01.2016, 01:16
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,746
Ïîáëàãîäàðèëè 33,410 ðàç(à) çà 31,755 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
êàê ïðèìåð, êîãäà ëåâîôëîêñàöèí ó îíêî-ïàöèåíòîâ ñ íåéòðîïåíèåé ñïîñîáñòâóåò ñíèæåíèþ òåìïåðàòóðû è âîññòàíîâëåíèþ àáñ. ÷èñëà íåéòðîôèëîâ >1500 çà 3 äíÿ:

Oral levofloxacin was effective and well tolerated in 97.6% of patients irrespective of the cancer type and cause of fever. Body temperature began to decline in 24.4, 68.3, and 90.2% of patients, respectively, at 12, 24, and 48 h after initiating levofloxacin therapy. On days 5 and 7, 95.1 and 97.6% of the patients had complete defervescence, respectively. The median time for absolute neutrophil count recovery to at least 1500/mm after initiation of treatment was 3 days. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Ïóáëèêàöèè ïîñëåäíèõ ëåò ïîêàçûâàþò, ÷òî ìîíîòåðàïèÿ ôòîðõèíîëîíîì - ïðèåìëåìàÿ îïöèÿ êàê äëÿ âçðîñëûõ ñ íåéòðîïåíèåé, òàê è äàæå äåòåé (íåñìîòðÿ íà òó ÷óøü, ÷òî íàïèñàíà â èíñòðóêöèè, ÷òî ÔÕ ïðîòèâîïîêàçàíû ó äåòåé):

Single-agent, broad-spectrum fluoroquinolones for the outpatient treatment of low-risk febrile neutropenia. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Fluoroquinolones in children with fever and neutropenia: a systematic review of prospective trials. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #4  
Ñòàðûé 14.01.2016, 01:37
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,746
Ïîáëàãîäàðèëè 33,410 ðàç(à) çà 31,755 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
ÔÕ-èíäóöèðîâàííóþ òðîìáîöèòîïåíèþ âñå ÷àùå è ÷àùå âûÿâëÿþò è äàæå îáçîð ïî íåé îòäåëüíûé èìååòñÿ:

Fluoroquinolone-induced immune thrombocytopenia: a report and review. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

íî îïÿòü æå, åñëè òðîìáîöèòîïåíèÿ èç-çà ñåïñèñà (ÄÂÑ) èëè èíôåêöèè, òî íàçíà÷åíèå ëþáîãî ÷óâñòâ. ÀÁ è ýðàäèêàöèÿ èíôåêöèè ïðèâåäåò ê íîðìàëèçàöèè òðîìáîöèòîâ, òîãäà êàê ñòðàõ ïåðåä íàçíà÷åíèåì ÔÕ èç-çà åäèíñòâåííîãî ñëó÷àÿ â ïðàêòèêå, ìîæåò ñòîèòü ïàöèåíòó æèçíè.

Êñòàòè, îáùåìèðîâûìè ñòàíäàðòàìè ïîäòâåðæäåíèÿ òîãî, ÷òî èìóííàÿ íåéòðîïåíèÿ/òðîìáîöèòîïåíèÿ âûçâàíà èìåííî ýòèì ëåêàðñòâîì, ÿâëÿþòñÿ: âûÿâëåíèå ñïåöèôè÷åñêèõ àíòèòåë, ðåàãèðóþùèõ ñ ñîîòâ. êëåòêàìè ïàöèåíòà â ïðèñóòñòâèè äàíîãî ëåêàðñòâà èëè ïîâòîðåíèå öèòîïåíèè ó îäíîãî è òîãî æå ïàöèåíòà, îáóñëîâëåííàÿ íàçíà÷åíèåì òîãî æå ëåêàðñòâà. Îäíîêðàòíîå îáíàðóæåíèå íåéòðî-òðîìáî-öèòîïåíèè ïîñëå íàçíà÷åíèÿ ëåêàðñòâà ñ÷èòàåòñÿ ñëó÷àéíûì.
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #5  
Ñòàðûé 14.01.2016, 01:46
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,746
Ïîáëàãîäàðèëè 33,410 ðàç(à) çà 31,755 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âîò ôðàãìåíò êðèòåðèåâ, êîãäà ìîæíî ñ÷èòàòü, ÷òî ìåæ íàçíà÷åíèåì ëåêàðñòâà è òðîìáîöèòîïåíèåé èìååòñÿ ïðè÷èííî-ñëåäñòâåííàÿ ñâÿçü:

To help establish the likelihood that a particular drug was the cause of the thrombocytopenia, several clinical scoring systems have been developed. In 1982 Hackett et al proposed the following criteria:
(1) Thrombocytopenia developed while the patient is taking the drug, resolved once the drug is stopped and did not recur while the patient was off the drug;
(2) other causes of thrombocytopenia were excluded;
(3) the thrombocytopenia recurred upon re-administration of the drug; and
(4) an in vitro test for drug-dependent platelet antibodies was positive [48].
A positive re-challenge or positive laboratory test was sufficient to confirm the diagnosis.

î÷åíü ÷àñòî ìíîãèå âðà÷è ñ÷èòàþò, ÷òî íàëè÷èå òîëüêî ïåðâîãî êðèòåðèÿ äîñòàòî÷íî äëÿ äèàãíîçà - öèòîïåíèÿ ðàçâèëàñü, ïîêà ïàöèåíò ïðèíèìàë ëåêàðñòâî, è ïðîõîäèò, êîãäà îí ïåðåñòàåò åãî ïðèíèìàòü...

PS. åùå áûâàåò ïñåâäîòðîìáîöèòîïåíèÿ (ñëèïàíèå òðîìáîöèòîâ â ÝÄÒÀ-ïðîáèðêå) íà ôîíå íàçíà÷åíèÿ àíòèáèîòèêîâ:

A 70 year-old woman was prescribed of levofloxacin and ceftriaxone for acute bronchitis. On the seventh day of administration she was hospitalized with a dry cough and a decreased platelet count (21 x 10(3)/microliter). However, bleeding tendency was not seen. So, we changed anticoagulants with citric acid and heparin from EDTA, and measured platelet count because we suspected pseudothrombocytopenia (PTCP), then platelet count became elevated (respectively, 125 x 10(3)/microliter and 150 x 10(3)/microliter). In addition, platelet associated IgG increased to 309.3 ng/10(7) cells. Based on drug lymphocyte stimulation test, she was diagnosed as having antibiotic-induced PTCP, especially as she had no history of thrombocytopenia. PTCP should be considered when thrombocytopenia occurs during antibiotic treatment
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Êîììåíòàðèè ê ñîîáùåíèþ:
Tarja îäîáðèë(à):
Assandra îäîáðèë(à): ñïàñèáî
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #6  
Ñòàðûé 27.01.2016, 20:11
Àâàòàð äëÿ Alexey2301
Alexey2301 Alexey2301 âíå ôîðóìà ÂÐÀ×
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 10.01.2010
Ãîðîä: Ñàìàðà
Ñîîáùåíèé: 355
Ñêàçàë(à) ñïàñèáî: 19
Ïîáëàãîäàðèëè 68 ðàç(à) çà 65 ñîîáùåíèé
Alexey2301 ýòîò ó÷àñòíèê èìååò îòëè÷íóþ ðåïóòàöèþ íà ôîðóìå
Ê ñîæàëåíèþ ïàöèåíòêà ïîãèáëà, îæèäàëè áðîíõîàëüâåîëÿðíûé ðàê, íî âñêðûòèå äàííûé äèàãíîç íå ïîäòâåðäèëî, íî è ïîëíîé ÿñíîñòè íåò. Ïî äàííûì ãèñòîëîãèè àëüâåîëÿðíî-ìàêðîôàãàëüíàÿ èíôèëüòðàöèÿ ë¸ãî÷íîé òêàíè ïî çàêëþ÷åíèþ ïàòîëîãîàíàòîìà ÈÇË. Ìàêðîñêîïè÷åñêè â ë¸ãêèõ ãðóáàÿ ôèáðîçíàÿ òêàíü.
Ìî¸ ïðåäïîëîæåíèå: âòîðè÷íàÿ îðãàíèçóþùàÿñÿ ïíåâìîíèÿ íà ôîíå òåïåðü óæå íåâûÿñíåííîé ïàòîëîãèè (ÑÇÑÒ êàê äåáþò â âèäå ÎÏ ðåçèñòåíòíîé ê ãîðìîíàì? îíêîãåìàòîëîãèÿ?). À óçëîâàòàÿ ýðèòåìà - ïàðàíåîïëàñòè÷åñêîå ïðîÿâëåíèå èëè ïðîÿâëåíèå ÑÇÑÒ. Âîò ãðèáêîâîãî ïîðàæåíèÿ ë¸ãî÷íîé òêàíè íå áûëî.
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 11:33.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.